Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: Viridian - The Real Truth

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza

William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday.

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

Viridian Therapeutics, Inc. (NASDAQ:VRDN) reported upbeat results for the second quarter on Wednesday.

Best conception supplements to boost fertility and support a healthy pregnancy

Best conception supplements to boost fertility and support a healthy pregnancy

Planning to get pregnancy? Help your chances with our pick of the best prenatal supplements

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Top Small-Cap Tech Picks for Investors This Month

Wall Street believes these three small companies have significant upside potential.

EVE Online celebrates 20th anniversary with a fireworks show and a free expansion

Viridian is set to come out in June.

Viridian Cannabis Credit Rankings Prioritize Liquidity

Over the last two weeks, TerrAscend (OTC: TRSSF), Verano (OTC: VRNOF), and Acreage (OTC: ACRDF) have obtained new credit agreements with interest rates in the low teens, demonstrating tha

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

inkl

Read news from The Economist, FT, and more,
with one subscription

'The World's Largest Database Of Cannabis Deals Gives Us Incredible Market Intelligence And An Edge,' Says Viridian's Scott Greiper

'The World's Largest Database Of Cannabis Deals Gives Us Incredible Market Intelligence And An Edge,' Says Viridian's Scott Greiper

Lowered valuations for cannabis companies are leading to a shift in the way capital is raised and merger and acquisition activity is occurring in the cannabis space. In this context, cannabis investors can leverage their understanding of M&A to anticipate corporate strategic moves and profit.

1

People

Rhian Stephenson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Gilead Sciences

US Food and Drug Administration

Nature Medicine

Medicines and Healthcare products Regulatory Agency

Viridian Cannabis Deal Tracker

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Multiple Sclerosis

Places

137,633 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play